Black Diamond Therapeutics, Inc. (BDTX)

US — Healthcare Sector
Peers:   PASG  TCRR  HARP  ALEC  RVMD  BCEL  STOK  FIXX  ADAP 

Automate Your Wheel Strategy on BDTX

With Tiblio's Option Bot, you can configure your own wheel strategy including BDTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol BDTX
  • Rev/Share 0.0
  • Book/Share 2.4975
  • PB 0.9009
  • Debt/Equity 0.1264
  • CurrentRatio 9.2408
  • ROIC -0.0251

 

  • MktCap 127940850.0
  • FreeCF/Share 0.4771
  • PFCF 4.7329
  • PE 25.0429
  • Debt/Assets 0.1015
  • DivYield 0
  • ROE 0.047

 

  • Rating B+
  • Score 3
  • Recommendation Neutral
  • P/E Score 2
  • DCF Score 3
  • P/B Score 4
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Black Diamond Therapeutics Trades Well Below Cash After Lucrative Deal With Servier
BDTX
Published: March 25, 2025 by: Seeking Alpha
Sentiment: Positive

Black Diamond Therapeutics' strategic deal with Servier makes BDTX undervalued, with a $70M upfront payment and potential $710M in milestone payments and royalties. BDTX is trading below its net cash of $2.30 per share, presenting a major buying opportunity despite past shareholder losses. Aggressive selling by Biotech Growth N.V. caused recent price volatility, but this creates a buying opportunity given BDTX's strong fundamentals.

Read More
image for news Black Diamond Therapeutics Trades Well Below Cash After Lucrative Deal With Servier

About Black Diamond Therapeutics, Inc. (BDTX)

  • IPO Date 2020-01-31
  • Website https://www.blackdiamondtherapeutics.com
  • Industry Biotechnology
  • CEO Dr. Mark A. Velleca M.D., Ph.D.
  • Employees 24
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.